CA2741481A1 - Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products - Google Patents
Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products Download PDFInfo
- Publication number
- CA2741481A1 CA2741481A1 CA2741481A CA2741481A CA2741481A1 CA 2741481 A1 CA2741481 A1 CA 2741481A1 CA 2741481 A CA2741481 A CA 2741481A CA 2741481 A CA2741481 A CA 2741481A CA 2741481 A1 CA2741481 A1 CA 2741481A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cell culture
- cells
- bioreactor
- matrix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 65
- 238000004113 cell culture Methods 0.000 title claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 54
- 230000010412 perfusion Effects 0.000 title claims abstract description 46
- 210000004027 cell Anatomy 0.000 claims description 251
- 239000011159 matrix material Substances 0.000 claims description 75
- 239000000047 product Substances 0.000 claims description 54
- 230000010261 cell growth Effects 0.000 claims description 34
- 239000012530 fluid Substances 0.000 claims description 34
- 238000003306 harvesting Methods 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 27
- 230000012010 growth Effects 0.000 claims description 27
- 239000007789 gas Substances 0.000 claims description 23
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 22
- 239000006143 cell culture medium Substances 0.000 claims description 20
- 239000002609 medium Substances 0.000 claims description 16
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 14
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 12
- 238000004891 communication Methods 0.000 claims description 9
- 230000001351 cycling effect Effects 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
- 230000007246 mechanism Effects 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 239000001301 oxygen Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 239000013589 supplement Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 5
- -1 polyethylene terephthalate Polymers 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 239000013603 viral vector Substances 0.000 claims description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 230000019522 cellular metabolic process Effects 0.000 claims description 3
- 210000003040 circulating cell Anatomy 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 230000008093 supporting effect Effects 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 230000001276 controlling effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 239000012533 medium component Substances 0.000 claims 1
- 238000005086 pumping Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 20
- 210000000130 stem cell Anatomy 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 16
- 239000012510 hollow fiber Substances 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 16
- 235000015097 nutrients Nutrition 0.000 description 14
- 239000012528 membrane Substances 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 10
- 239000002699 waste material Substances 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000010899 nucleation Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000004886 process control Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 5
- 108010000521 Human Growth Hormone Proteins 0.000 description 5
- 239000000854 Human Growth Hormone Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- 229920000515 polycarbonate Polymers 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229960004854 viral vaccine Drugs 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000004700 fetal blood Anatomy 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 238000006213 oxygenation reaction Methods 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000011923 Thyrotropin Human genes 0.000 description 3
- 108010061174 Thyrotropin Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000002572 peristaltic effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000005204 segregation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 230000001228 trophic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 108010017544 Glucosylceramidase Proteins 0.000 description 2
- 102000004547 Glucosylceramidase Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010054267 Interferon Receptors Proteins 0.000 description 2
- 102000001617 Interferon Receptors Human genes 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 108010057021 Menotropins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108010079274 Thrombomodulin Proteins 0.000 description 2
- 102000012607 Thrombomodulin Human genes 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 108010085650 interferon gamma receptor Proteins 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 102000044166 interleukin-18 binding protein Human genes 0.000 description 2
- 108010070145 interleukin-18 binding protein Proteins 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 229960004532 somatropin Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 108700002109 Transmembrane Activator and CAML Interactor Proteins 0.000 description 1
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000006177 biological buffer Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 108010046910 brain-derived growth factor Proteins 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001011 carotid body Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical class CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000000399 corneal endothelial cell Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 102000026898 cytokine binding proteins Human genes 0.000 description 1
- 108091008470 cytokine binding proteins Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000000865 membrane-inlet mass spectrometry Methods 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- SYXUBXTYGFJFEH-UHFFFAOYSA-N oat triterpenoid saponin Chemical compound CNC1=CC=CC=C1C(=O)OC1C(C=O)(C)CC2C3(C(O3)CC3C4(CCC5C(C)(CO)C(OC6C(C(O)C(OC7C(C(O)C(O)C(CO)O7)O)CO6)OC6C(C(O)C(O)C(CO)O6)O)CCC53C)C)C4(C)CC(O)C2(C)C1 SYXUBXTYGFJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002797 pancreatic ductal cell Anatomy 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000009428 plumbing Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GLFDLEXFOHUASB-UHFFFAOYSA-N trimethyl(tetradecyl)azanium Chemical class CCCCCCCCCCCCCC[N+](C)(C)C GLFDLEXFOHUASB-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000005924 vaccine-induced immune response Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/42—Integrated assemblies, e.g. cassettes or cartridges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/28—Constructional details, e.g. recesses, hinges disposable or single use
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/44—Multiple separable units; Modules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Clinical Laboratory Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10764408P | 2008-10-22 | 2008-10-22 | |
| US61/107,644 | 2008-10-22 | ||
| PCT/US2009/061700 WO2010048417A2 (en) | 2008-10-22 | 2009-10-22 | Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2741481A1 true CA2741481A1 (en) | 2010-04-29 |
Family
ID=42119984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2741481A Abandoned CA2741481A1 (en) | 2008-10-22 | 2009-10-22 | Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110212493A1 (enExample) |
| EP (1) | EP2346984A4 (enExample) |
| JP (1) | JP2012506257A (enExample) |
| AU (1) | AU2009308354A1 (enExample) |
| CA (1) | CA2741481A1 (enExample) |
| IL (1) | IL212387A0 (enExample) |
| WO (1) | WO2010048417A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007012238D1 (de) | 2006-05-22 | 2011-03-10 | Biovest Internat Inc | Ahren |
| EP2609189A4 (en) * | 2010-08-24 | 2015-08-05 | Hawley & Hazel Chemical Co Zhongshan Ltd | METHODS, DEVICES AND USES RELATED TO BIOFILMS |
| WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
| WO2012079086A2 (en) * | 2010-12-10 | 2012-06-14 | Florida State University Research Foundation, Inc. | Mesenchymal stem cells (msc) expansion methods and materials |
| EP2714886B1 (en) * | 2011-05-30 | 2020-01-22 | Atech Partners Ltd. | Bioreactor system for continuous cell cultivation |
| WO2012171026A2 (en) * | 2011-06-10 | 2012-12-13 | Biovest International, Inc. | Methods for high yield virus production |
| WO2012171030A2 (en) | 2011-06-10 | 2012-12-13 | Biovest International, Inc. | Method and apparatus for antibody production and purification |
| SG11201401135XA (en) * | 2011-10-07 | 2014-10-30 | Pall Technology Uk Ltd | Fluid processing control system and related methods |
| US9683207B2 (en) | 2012-05-01 | 2017-06-20 | FiberCell Production Solutions LLC | Method for growing cells in hollow fibers |
| WO2014031690A1 (en) * | 2012-08-20 | 2014-02-27 | Terumo Bct, Inc. | Concentrating components of fluid circulated through a cell growth chamber |
| CA2920957A1 (en) * | 2012-08-28 | 2014-03-06 | Biovest International, Inc. | Biomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules |
| US9725768B2 (en) | 2012-08-31 | 2017-08-08 | Biovest International, Inc. | Methods for producing high-fidelity autologous idiotype vaccines |
| PL2739720T3 (pl) | 2012-09-06 | 2015-06-30 | Pluristem Ltd | Układy i sposoby hodowli komórek |
| EP2706112A1 (en) * | 2012-09-06 | 2014-03-12 | Université Catholique De Louvain | Fluidic device for studying of surface-dwelling multicellular layers and microbial biofilms |
| ES2489315B1 (es) * | 2013-01-16 | 2015-09-09 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Cámara de cultivo celular sobre biomateriales |
| MX369522B (es) | 2013-02-22 | 2019-11-11 | Genzyme Corp | Metodos de cultivo por perfusión con microportadores y usos de los mismos. |
| US10900023B2 (en) | 2013-08-22 | 2021-01-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Modular, microfluidic, mechanically active bioreactor for 3D, multi-tissue, tissue culture |
| WO2015048712A2 (en) * | 2013-09-30 | 2015-04-02 | Weyerhaeuser Nr Company | Independent ports in automated bioreactor system |
| WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| WO2015118146A1 (en) | 2014-02-10 | 2015-08-13 | Univercells Nv | System, apparatus and method for biomolecules production |
| EP3110428A4 (en) * | 2014-02-28 | 2017-11-22 | Bdbc Sciences Corp. | A system for tissue manipulation |
| US10039244B2 (en) * | 2014-03-04 | 2018-08-07 | Greenonyx Ltd | Systems and methods for cultivating and distributing aquatic organisms |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| JP6719387B2 (ja) * | 2014-04-28 | 2020-07-08 | ビババイオセル エスピーエー | 自動細胞培養及び回収装置 |
| TWI743024B (zh) | 2014-06-06 | 2021-10-21 | 美商健臻公司 | 灌注培養方法及其用途 |
| WO2016049421A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled feed |
| WO2016093321A1 (ja) * | 2014-12-11 | 2016-06-16 | 株式会社アイカムス・ラボ | 細胞培養方法及び細胞培養装置 |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| US11154858B2 (en) | 2015-10-06 | 2021-10-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Microfluidic tissue development systems |
| BR112018008055A2 (pt) | 2015-10-20 | 2018-10-23 | Locus Solutions Llc | aparelho, sistema e métodos para crescimento de microorganismos |
| WO2017087535A1 (en) * | 2015-11-17 | 2017-05-26 | Oregon State University | Bio-lamina bioreactors and methods of making and using the same |
| KR20240173213A (ko) * | 2016-01-26 | 2024-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 연결된 관류 대 연속-유동식 교반-탱크 반응기 세포 배양 시스템 |
| US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| GB2554635A (en) * | 2016-08-03 | 2018-04-11 | Northwick Park Institute For Medical Res Ltd | Bioreactors and methods for processing biological material |
| JP6942448B2 (ja) * | 2016-08-08 | 2021-09-29 | 株式会社カネカ | 細胞培養容器、これを用いた細胞培養システム、および細胞培養方法 |
| US12234441B2 (en) | 2017-03-31 | 2025-02-25 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| TWI675696B (zh) * | 2017-06-01 | 2019-11-01 | 美商Ｅｍｄ密理博公司 | 用於灌注應用之切向流過濾裝置 |
| KR102176500B1 (ko) | 2017-07-21 | 2020-11-09 | 포항공과대학교 산학협력단 | 관류식 바이오 리액터를 사용한 세포밖 소포체 분비량 향상 방법 및 이를 위한 시스템 |
| US11680241B2 (en) | 2018-02-08 | 2023-06-20 | University Of Florida Research Foundation, Inc. | Perfusion enabled bioreactors |
| JPWO2020013221A1 (ja) * | 2018-07-12 | 2021-07-15 | 日本曹達株式会社 | 培養装置、担体、および培養対象回収方法 |
| JP7133409B2 (ja) * | 2018-09-18 | 2022-09-08 | テルモ株式会社 | バイオリアクタ、細胞培養システム及び細胞培養方法 |
| JP7133410B2 (ja) * | 2018-09-18 | 2022-09-08 | テルモ株式会社 | バイオリアクタ、細胞培養システム及び細胞培養方法 |
| IL263127B (en) * | 2018-11-19 | 2022-07-01 | The Interdisciplinary Center Herzliya Cc | A liquid-based biological system |
| CA3123449A1 (en) * | 2018-12-21 | 2020-06-25 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| US11692161B2 (en) | 2019-02-05 | 2023-07-04 | Corning Incorporated | Packed-bed bioreactor systems and methods of using the same |
| CA3200542A1 (en) | 2019-05-28 | 2020-12-03 | Upside Foods, Inc. | Apparatuses and methods for preparing a comestible meat product |
| EP4023746A4 (en) * | 2019-08-29 | 2023-11-01 | Fanuc Corporation | CELL PRODUCTION DEVICE |
| US11118151B2 (en) | 2019-11-05 | 2021-09-14 | Corning Incorporated | Fixed bed bioreactor and methods of using the same |
| IL292318B2 (en) | 2019-11-20 | 2023-04-01 | Upside Foods Inc | Devices and methods for preparing a meat product |
| WO2021108089A1 (en) * | 2019-11-27 | 2021-06-03 | Corning Incorporated | Radial flow fixed bed bioreactor and methods of using the same |
| KR102417445B1 (ko) * | 2019-11-29 | 2022-07-06 | 주식회사 아모그린텍 | 세포배양장치 |
| USD961115S1 (en) * | 2020-01-20 | 2022-08-16 | Adva Biotechnology Ltd. | Bioreactor cabinet |
| AU2021253701B2 (en) * | 2020-04-10 | 2024-05-02 | Southwest Research Institute | Three-dimensional bioreactor for viral vector production |
| GB2619893A (en) | 2021-03-23 | 2023-12-20 | Terumo Bct Inc | Cell capture and expansion |
| US11752509B2 (en) | 2021-06-17 | 2023-09-12 | Upside Foods, Inc. | Fluid dispenser for recovering material from a surface |
| US20230066039A1 (en) * | 2021-09-01 | 2023-03-02 | Global Life Sciences Solutions Usa Llc | Perfusion filter membrane and method of use |
| US12241050B2 (en) | 2021-09-01 | 2025-03-04 | Global Life Sciences Solutions Usa, Llc | Perfusion filter assembly for increased cross flow |
| WO2023121655A1 (en) * | 2021-12-21 | 2023-06-29 | Bayer Aktiengesellschaft | Improved cell culture method |
| US20250171742A1 (en) * | 2022-02-28 | 2025-05-29 | University Of Georgia Research Foundation, Inc. | Bioreactor for cell expansion and cultivation |
| US12209689B2 (en) | 2022-02-28 | 2025-01-28 | Terumo Kabushiki Kaisha | Multiple-tube pinch valve assembly |
| USD1099116S1 (en) | 2022-09-01 | 2025-10-21 | Terumo Bct, Inc. | Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device |
| WO2024073071A1 (en) * | 2022-09-29 | 2024-04-04 | The University Of Akron | Chamber assembly for ex-vivo electroretinogram with filleted perfusion inlet and outlet |
| US11981884B2 (en) | 2022-10-17 | 2024-05-14 | Upside Foods, Inc. | Pipe-based bioreactors for producing comestible meat products and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4804628A (en) * | 1984-10-09 | 1989-02-14 | Endotronics, Inc. | Hollow fiber cell culture device and method of operation |
| US5266476A (en) * | 1985-06-18 | 1993-11-30 | Yeda Research & Development Co., Ltd. | Fibrous matrix for in vitro cell cultivation |
| US5786215A (en) * | 1987-05-20 | 1998-07-28 | Baxter International Inc. | Method for culturing animal cells |
| DE3923279A1 (de) * | 1989-07-14 | 1990-01-18 | Will W Prof Dr Minuth | Minusheets ist ein neues produkt, um zellen in beliebigen behaeltnissen in hochdifferenzierter form auf einer moeglichst natuerlichen unterlage zu kultivieren |
| US5126269A (en) * | 1990-09-13 | 1992-06-30 | Life Techologies, Inc. | Spin filter perfusion bioreactor (sfpb) cell culture apparatus |
| US6372482B1 (en) * | 1997-01-16 | 2002-04-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Device and method for performing a biological modification of a fluid |
| BE1009306A5 (fr) * | 1995-04-28 | 1997-02-04 | Baxter Int | Bioreacteur. |
| WO1998050522A1 (en) * | 1997-05-07 | 1998-11-12 | Baxter International Inc. | Method and apparatus for high volume production of viral particles |
| US6875605B1 (en) * | 2002-08-21 | 2005-04-05 | Florida State University Research Foundation, Inc. | Modular cell culture bioreactor and associated methods |
| US6943008B1 (en) * | 2002-08-21 | 2005-09-13 | Florida State University Research Foundation, Inc. | Bioreactor for cell culture |
| US7534601B2 (en) * | 2002-08-27 | 2009-05-19 | Vanderbilt University | Capillary perfused bioreactors with multiple chambers |
| CN103173354B (zh) * | 2003-10-08 | 2017-07-14 | 威尔森沃尔夫制造公司 | 利用透气性材料进行细胞培养的方法及装置 |
| US7767446B2 (en) * | 2004-09-16 | 2010-08-03 | Becton, Dickinson And Company | Perfusion bioreactors for culturing cells |
| JP4639799B2 (ja) * | 2004-12-27 | 2011-02-23 | カシオ計算機株式会社 | カメラ装置、レンズ駆動方法 |
| WO2007071072A1 (en) * | 2005-12-22 | 2007-06-28 | Corporation De L'ecole Polytechnique De Montreal | High-rate perfusion bioreactor |
| DE602007012238D1 (de) * | 2006-05-22 | 2011-03-10 | Biovest Internat Inc | Ahren |
-
2009
- 2009-10-22 WO PCT/US2009/061700 patent/WO2010048417A2/en not_active Ceased
- 2009-10-22 AU AU2009308354A patent/AU2009308354A1/en not_active Abandoned
- 2009-10-22 JP JP2011533338A patent/JP2012506257A/ja not_active Withdrawn
- 2009-10-22 EP EP09822715.0A patent/EP2346984A4/en not_active Withdrawn
- 2009-10-22 CA CA2741481A patent/CA2741481A1/en not_active Abandoned
-
2011
- 2011-04-14 IL IL212387A patent/IL212387A0/en unknown
- 2011-04-22 US US13/092,836 patent/US20110212493A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010048417A3 (en) | 2010-08-19 |
| EP2346984A2 (en) | 2011-07-27 |
| US20110212493A1 (en) | 2011-09-01 |
| JP2012506257A (ja) | 2012-03-15 |
| EP2346984A4 (en) | 2013-10-30 |
| IL212387A0 (en) | 2011-06-30 |
| WO2010048417A2 (en) | 2010-04-29 |
| AU2009308354A1 (en) | 2010-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110212493A1 (en) | Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products | |
| US10662401B2 (en) | Biomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules | |
| US10844338B1 (en) | Automated tissue engineering system | |
| JPH078274A (ja) | 膜バイオリアクター中の物質移動を改良する方法及び装置 | |
| AU2012205259B2 (en) | Automated tissue engineering system | |
| Goltry et al. | Large-scale production of adult stem cells for clinical use | |
| CN110669669A (zh) | 一种模块化三维灌注细胞培养系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20141022 |